http://orcid.org/0000-0002-1068-4261
References
- Center for Drug Evaluation and Research. (2017). In Vitro Metabolism- and Transporter-Mediated Drug–Drug Interaction Studies Guidance for Industry: Draft Guidance. Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm581965.pdf [last accessed 14 Nov 2019].
- Committee for Human Medicinal Products. (2012). Guideline on the Investigation of Drug Interactions. London: European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 14 Nov 2019].
- Harwood MD, Neuhoff S, Carlson GL, et al. (2013). Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos 34:2–28.
- Ishibashi S, Arai H, Yokote K, et al. (2018). Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12:173–84.
- Jamei M, Bajot F, Neuhoff S, et al. (2014). A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73–87.
- Jamei M, Marciniak S, Feng K, et al. (2009). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211–23.
- Johnson TN, Boussery K, Rowland-Yeo K, et al. (2010). A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189–206.
- Kamiya Y, Otsuka S, Miura T, et al. (2019). Plasma and hepatic concentrations of chemicals after virtual oral administrations extrapolated using rat plasma data and simple physiologically based pharmacokinetic models. Chem Res Toxicol 32:211–8.
- Kim SJ, Lee KR, Miyauchi S, Sugiyama Y. (2019). Extrapolation of in vivo hepatic clearance from in vitro uptake clearance by suspended human hepatocytes for anionic drugs with high binding to human albumin: improvement of in vitro-to-in vivo extrapolation by considering the “albumin-mediated” hepatic uptake mechanism on the basis of the “facilitated-dissociation model”. Drug Metab Dispos 47:94–103.
- Li R, Barton HA, Maurer TS. (2015). A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions. CPT Pharmacometrics Syst Pharmacol 4:338–49.
- Lin W, Ji T, Einolf H, et al. (2017). Evaluation of drug–drug interaction potential between sacubitril/valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model. J Pharm Sci 106:1439–51.
- Ogawa S-i, Tsunenari Y, Kawai H, Yamazaki H. (2019). Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys. Biopharm Drug Dispos 40:12–7.
- Parmentier Y, Pothier C, Hewitt N, et al. (2019). Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model. Xenobiotica 49:22–35.
- Xia CQ, Liu N, Miwa GT, Gan L-S. (2007). Interactions of cyclosporin A with breast cancer resistance protein. Drug Metab Dispos 35:576–82.
- Yokote K, Yamashita S, Arai H, et al. (2019). Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα), in dyslipidemic patients with renal impairment. Int J Mol Sci 20: pii: E706.